国际皮肤性病学杂志    2004 30 (6): 375-377   ISSN: 2096-5540  CN: 32-1880/R   5α-还原酶在雄激素代谢中的作用及其抑制剂在皮肤科的应用 尹兴平, 夏隆庆 中国医学科学院、中国协和医科大学皮肤病研究所 南京 210042 收稿日期 2003-12-08  修回日期 null  网络版发布日期 null 参考文献  [1] Labrie F, Luu-The V, Labrie C, et al. Intracrinology and the skin.Horm Res, 2000, 54:218-229. [2] Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol, 2003, 120:905-914. [3] Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol,1999, 135:1041-1045. [4] De Villez RL, Dunn J. Female androgenic alopecia. The 3 alpha,17beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. Arch Dermatol, 1986,122:10ll-1015. [5] Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and Ⅱ, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dennatol, 1997, 109:296-300. [6] Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol, 1999, 141:481-491. [7] Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol, 1998,110:849-853. [8] Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol, 1998, 39:578-589. [9] Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol, 1999, 41:550-554. [10] Price VH, Menefee E, Sanchez M, et al. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol, 2002, 46:517-523. [11] Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol, 2000, 43:768-776. [12] Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab, 1995, 80:233-238. [13] Qian LH, Wang XL, Tu ZH. Atrophy and apoptosis in ventral prostate of rats induced by 5alpha-reductase inhibitor, epristeride. Acta Pharmacol Sin, 2001, 22:399-404. [14] Graul A,Silvestre J, Castaner J, et al. Dutasteride, steroid 5α-reductase inhibitor, treatment of BPH. Drugs Fut, 1999, 24:246-253. [15] Fujita T, Matsumoto Y, Kimura T, et al. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol, 2002, 54:283-294. [16] Hirosumi J, Nakayama O, Chida N, et al. FK.143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates. J Steroid Biochem Mol Biol, 1995, 52:365-373. [17] Sawada K, Okada S, Kuroda A, et al. 4-(Benzoylindolizinyl)butyric acids; novel nonsteroidal inhibitors of steroid 5alpha-reductase. Ⅲ.Chem Pharm Bull (Tokyo), 2001,49:799-813. [18] Niiyama S, Kojima K, Hamada T, et al. The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol, 2000, 10:593-595. [19] Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol, 2002,19:413-425. 通讯作者: